Judge Sides With Par in Novartis’s Patent Infringement Lawsuit Over Exelon

Drug Industry Daily
A A
A federal judge has ruled that Par Pharmaceutical’s generic version of the Novartis Alzheimer’s treatment Exelon Patch did not infringe on the brand manufacturer’s patent.

To View This Article:

Login

Subscribe To Drug Industry Daily